Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalties
Biotech
Gilead pays J&J $320M to exit licensing deal for seladelpar
With Gilead on the verge of an FDA decision for seladelpar, it has paid J&J $320M to exit an 18-year-old licensing agreement on the drug.
Kevin Dunleavy
Aug 9, 2024 10:30am
Ovid sells some royalty rights to Takeda-partnered seizure drug
Oct 18, 2023 8:00am
Blackstone, Sutro ink royalty pact worth up to $390M biobucks
Jun 26, 2023 1:47pm
Arrowhead fills quiver with $250M Royalty deal
Nov 9, 2022 11:00am
